dc.contributor.author | Ozbalak, Murat | |
dc.contributor.author | Ar, M. Cem | |
dc.contributor.author | Tuzuner, Nukhet | |
dc.contributor.author | Salihoglu, Ayse | |
dc.contributor.author | Eskazan, A. Emre | |
dc.contributor.author | Ongoren Aydin, Seniz | |
dc.contributor.author | Baslar, Zafer | |
dc.contributor.author | Soysal, Teoman | |
dc.contributor.author | Aydin, Yildiz | |
dc.contributor.author | Barak Dolgun, Anil | |
dc.contributor.author | Ergonul, Onder | |
dc.contributor.author | Ferhanoglu, Burhan | |
dc.date.accessioned | 2019-12-12T06:24:10Z | |
dc.date.available | 2019-12-12T06:24:10Z | |
dc.date.issued | 2013 | |
dc.identifier.issn | 2090-441X | |
dc.identifier.uri | https://doi.org/10.1155/2013/908191 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747433/ | |
dc.identifier.uri | http://hdl.handle.net/11655/16134 | |
dc.description.abstract | The aim of this single-center, retrospective study was to investigate the impact of rituximab, reconsider the validity of International Prognostic Index (IPI), and evaluate the prognostic role of the cell of origin (CoO) in a relatively young cohort. Three hundred twelve diffuse large B cell lymphoma patients (median age: 52) were included. Rituximab significantly improved the 3- and 5-year progression free survival (PFS) (70% versus 65% and 41% versus 36%, resp.; P < 0.001) but led only to a slight, insignificant increase in 3- and 5-year overall survival (OS) (71% versus 77.3% and %67 versus 74.5%, resp.; P = 0.264). In the young, low risk patient subgroup (aaIPI = 0&1; n = 129), rituximab improved 3- and 5-year PFS and OS rates (P < 0.001 and P = 0.048, resp.). The efficacy of rituximab in young high risk patients was comparable to the literature. CoO data were available in 190 patients. The OS at 3 years was 79% for GC and 64% for non-GC subgroups (P = 0.014). To the best of our knowledge, this is the first study which investigated the impact of R-CHOP in the context of CoO and IPI in a relatively young cohort. CoO was not an independent risk factor for prognosis in the multivariate analysis although patients with GC showed a significant survival advantage in the univariate analysis. CoO was also found to be a significant determinant of response in refractory/relapsed patients. Our results confirm the efficacy of rituximab in low and high risk, young patients outside of a randomized clinical trial setting. | |
dc.language.iso | en | |
dc.relation.isversionof | 10.1155/2013/908191 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.title | Detailed Analysis Of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | ISRN Hematology | |
dc.contributor.department | Biyoistatistik | |
dc.identifier.volume | 2013 | |
dc.description.index | PubMed | |